Ackman: Valeant A "Good" Roll Up Firm, Strategy Synergies

Mark Melin

Published onJune 9, 2014

Updated on May 13, 2021

Bill Ackman was defending Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) today, upon which he is dependent on for a high stock price to fuel his hedge fund’s involvement in the Valeant / Allergan acquisition. The deal to purchase Allergan, Inc. (NYSE:AGN) is based in large part on the price of Valeant shares. In an interview with CNBC today, Ackman also talked about Valeant in terms of its value as a “roll up” company.

Table of Contents

Ackman teaming with Valeant to pressure Allergan

As previously reported in ValueWalk, Ackman approached Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), a...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mark Melin

Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.

Ackman: Valeant A "Good" Roll Up Firm, Strategy Synergies

Ackman teaming with Valeant to pressure Allergan

Login required to continue reading.

Get Your Business News